Geron Corporation to Present at BIO CEO & Investor Conference
MENLO PARK, Calif., Feb 08, 2008 (BUSINESS WIRE) -- Geron Corporation (GERN)
today announced that Thomas B. Okarma, Ph.D., M.D., Geron's president and chief
executive officer, will present an update of the company's product development
programs at 11 a.m. ET on Monday, Feb. 11, 2008, at the BIO CEO & Investor
Conference in New York City.
The update of Geron's portfolio of telomerase-based anti-cancer therapies will
include the inhibitor drug, GRN163L, and the therapeutic vaccine, GRNVAC1. New
information about the company's second generation human embryonic stem cell-based
cancer vaccine, GRNVAC2, will also be presented. Additionally, the presentation
will include reviews of the company's human embryonic stem cell development
programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1) and diabetes
(GRNIC1).
An audio Webcast of the presentation will be available at the following Web site
address: corporate-ir.net |
